Section 11 damages computation for direct listings
In September 2021, the Ninth Circuit ruled in Pirani v. Slack Technologies, Inc.[1] (Slack) that Section 11 liability applies to direct listing shares. This...
CRA has a broad range of experience in complex shareholder lawsuits and appraisal disputes involving life sciences and healthcare companies. CRA assists clients across all phases of the securities litigation process, including responding to pre-litigation SEC investigations, class certification, discovery, materiality, loss causation, damages, and settlement negotiations. CRA supports clients in disputes arising from mergers and acquisitions by providing industry expertise in evaluating claims regarding drug development and commercialization and other issues. Our experts provide valuation opinions related appraisal lawsuits brought by dissenter or minority shareholders, and estimated damages related to shareholder disputes for breach of contingent valuation rights agreements.
Engagements
- 01Cigna-Anthem Merger LitigationCRA was retained by counsel for Cigna Corporation in a litigation in Delaware Chancery Court arising from its unsuccessful merger with Anthem, Inc. Both...View engagement
- 02CRA evaluates commercial efforts to develop a MS drug with respect to contractual obligations following mergerCRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by...View engagement
- 03CRA expert testifies in Chapter 11 case on behalf of Debtor, LTL Management LLCCRA was retained on behalf of LTL Management LLC, the Debtor in a bankruptcy case to opine on the impact that talc tort litigation had on the Johnson & Johnson...View engagement
Contact a Life Sciences Securities Litigation expert.
See all Life Sciences Securities Litigation experts.Recent events
IQVIA Institute Research Forum - Advancing Evidence with Large Datasets in High-Impact Health Research
Annabelle Fowler is a panelist during the session titled “Improving Sustainable Biomedical Innovation.” For more information on this event, click here.
6th Edition GAR Live: Damages
Andrew Tepperman is a panelist during the session titled “Damages issues in IP and life science disputes.” For more information on this event, click here.